CTIS2022-500318-24-00进行中（未招募）1 期
Evaluation of quantitative sensory testing (QST) using subcutaneous administration of single escalating doses of halneuron® (tetrodotoxin (TTX)) for injection in healthy volunteers
eiden University Medical Center0 个研究点目标入组 25 人开始时间: 2023年5月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Willingness to adhere to protocol requirements as evidenced by a valid informed consent form (ICF) duly signed by the subject., Generally healthy males and females, between 18 and 55 years of age (inclusive) with a body mass index (BMI) within 19-30 kg/m2., Minimum weight of 50 kg., Normal renal function (creatinine clearance from 80 to 180 mL/min per Cockroft-Gault equation., Clinical laboratory values within the laboratory's stated normal range. If not within this range, they must be considered not clinically significant by an investigator and must be recorded as such in the CRF., Physical examination within normal limits or considered not clinically significant by an Investigator., Supine blood pressure = 100/60 mmHg and = 160/100 mmHg and pulse rate > 50 bpm and < 100 bpm after 5 minutes of rest, at screening. Repeat measurements are allowed if initial readings are considered unrepresentative by the PI., Nonsmoker or ex-smoker (for a minimum of 6 months)., Women of childbearing potential and men must agree to use adequate contraception in the opinion of an investigator (e.g., hormonal or double-barrier method of birth control; abstinence) during the duration of study participation.
排除标准
- •Significant history of hypersensitivity to fish or tetrodotoxin or any related products., History of seizure disorder, concussion, or other clinically significant head or spine injury., Presence or history of significant cardiovascular, hematologic, psychiatric, endocrine, immunologic or dermatologic disease., History of malignancy., History of alcoholism considered excessive in the opinion of an investigator, within 12 months, or routine use of ethanol averaging > 3 units of alcohol per day., Maintenance therapy with any drug, or significant history of drug dependency, including prescription drug abuse., Any clinically significant illness in the previous 28 days before Day 1 of this study. A significant illness is an illness requiring hospitalization or an event that in the opinion of the Investigator no longer classifies the subject as a healthy volunteer”., Use of Botox (Botulinum Toxin Type A) in the past 3 months., Local or systemic exposure to lidocaine., The use of antidepressants or anticonvulsants with known voltage-gated sodium channel activity., Participation in another clinical trial with drug or device in the previous 30 days., History of anaphylaxis to a medication, dietary item, or environmental exposure (including bee stings)., Positive for human immunodeficiency virus (HIV) infection., Diagnosed with hepatitis B or hepatitis C virus infection., Females with a positive urine pregnancy test at screening, who are lactating, or at risk of pregnancy (i.e., sexually active with fertile males and not using an adequate form of birth control)., Subjects with loss or donation of 50 mL or more of blood in the previous 28 days before Day 1 of this study, or 500mL or more of blood in the previous 56 days before Day 1 of this study., Any condition which makes a candidate unsuitable for study participation, in the opinion of the PI., History of multiple, clinically significant drug allergies, Presence or history of significant gastrointestinal, liver, or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects., History of an obstructive pulmonary disease including asthma, emphysema, or chronic bronchitis., History or presence of any disorder resulting in clinically significant restrictive pulmonary disease., History or presence of Guillain-Barre syndrome, multiple sclerosis, myasthenia gravis, muscular dystrophy, or other neuropathy or myopathy., A clinically significant deficiency on the neurological part of the physical exam prior to enrollment., Diagnosis or symptoms suggesting central nervous system (CNS) disorders and peripheral nervous system disorders.
研究者
相似试验
进行中（未招募）
2 期
Tetrodotoxin and quantitative sensory testing in healthy volunteersPainSigns and SymptomsISRCTN78737401eiden University Medical Center25
已完成
不适用
Quantitative sensory testing (QST) protocol.NL-OMON34703PRA International EDS400
已完成
不适用
Quantitative Sensory Testing (QST) as a tool to assess and quantify thoracic pain in patients with chronic interstitial lung disease (ILD)J84.9R07.4Interstitial pulmonary disease, unspecifiedChest pain, unspecifiedDRKS00022978niversitätsmedizin Essen, Ruhrlandklinik79
招募中
不适用
Quantitative Sensory Testing (QST) in The Diagnostic & Therapeutic Process of patients with Painful Cervical Facet ArthropathyChronic Neck Pain1002321310005944NL-OMON34812niversitair Medisch Centrum Sint Radboud92
已完成
不适用
Quantitative Sensory Testing (QST) to establish a somatosensory phenotype in pulmonary surgery - Identification of risk factors and a sensitive predictor in QST testing for chronic post-thoracotomy pain and its neuropathic component.G89.22: Chronic post-thoracotomy painDRKS00015102niversitätsmedizin Essen, Ruhrlandklinik182